This clinical trial is testing how safe and tolerable the drug Venetoclax is when combined with chemotherapy for young patients with certain blood cancers. These cancers include myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL), among others. Venetoclax is a drug that may help stop cancer cells from surviving by targeting a protein called BCL-2. This trial is in Phase I, which means it's mainly trying to find the right dose and see how the body handles the drug.
- Participants could be in the trial for different periods, depending on how their body reacts to the drugs.
- There will be regular visits for treatment and follow-ups to ensure safety and track progress.
- Participants might receive different doses based on how previous participants have responded.
Before joining, participants will go through screening to check if they are eligible. It's important to know that the FDA has not approved Venetoclax for children, but it is approved for some adult leukemia treatments. Potential participants and families should consider the risks and benefits and discuss them with their healthcare provider.